An Exploratory, Double-blind, Randomized, Placebo-controlled, Single-center, Two-way Cross-over Study With KH176 in Patients With the Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation and Clinical Signs of Mitochondrial Disease

Trial Profile

An Exploratory, Double-blind, Randomized, Placebo-controlled, Single-center, Two-way Cross-over Study With KH176 in Patients With the Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation and Clinical Signs of Mitochondrial Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs KH 176 (Primary)
  • Indications Leber's hereditary optic atrophy; Leigh disease; MELAS syndrome; Mitochondrial disorders
  • Focus Proof of concept; Therapeutic Use
  • Acronyms KHENERGY
  • Sponsors Khondrion
  • Most Recent Events

    • 22 Nov 2017 According to a Khondrion media release, results from this trial were presented at the Dutch Life Sciences Conference.
    • 22 Nov 2017 Final results from this trial will be presented in Q1 2018, according to a Khondrion media release.
    • 22 Nov 2017 Results presented in a Khondrion media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top